Help
RSS
API
Feed
Maltego
Contact
Domain > www.us.adakveo.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2021-07-01
104.18.10.90
(
ClassC
)
2026-02-24
172.64.154.154
(
ClassC
)
Port 443
HTTP/1.1 200 OKDate: Tue, 24 Feb 2026 16:48:47 GMTContent-Type: text/html; charsetutf-8Transfer-Encoding: chunkedConnection: keep-aliveServer: cloudflarex-content-type-options: no-sniffx-xss-protection: 1; modeblockx-frame-options: SAMEORIGINstrict-transport-security: max-age63072000; includeSubDomainsx-dns-prefetch-control: onCache-Control: public, max-age3600, s-maxage2678400, stale-while-revalidate59content-security-policy: default-src usim.beprod.us.adakveo.com self; style-src cdn.pullthrough.tools cdn.uat.pullthrough.tools usim.beprod.us.adakveo.com prod.cz.hcp.novartis.com *.googleapis.com fonts.gstatic.com self unsafe-inline kms-a.akamaihd.net cfvod.kaltura.com; script-src zero-psa-locator.pages.dev www.knotch-cdn.com aim-tag.hcn.health cdn.pullthrough.tools uatservices.pullthrough.tools code.jquery.com cdn.uat.pullthrough.tools js-agent.newrelic.com/nr-rum-1.248.0.min.js usim.beprod.us.adakveo.com prod.cz.hcp.novartis.com unpkg.com kaltura.com *.kaltura.com contextweb.com *.contextweb.com bat.bing.com *.doubleclick.net tags.tiqcdn.com ipredictive.com *.ipredictive.com self unsafe-inline unsafe-eval blob: *.googleapis.com *.pmsrv.co t.contentsquare.net app.contentsquare.com static.cloudflareinsights.com *.meta.net mediahub.novartis.com match.deepintent.com trc.lhmos.com secure.adnxs.com *.facebook.net analytics.google.com *.analytics.google.com google-analytics.com *.google-analytics.com googletagmanager.com *.googletagmanager.com tagmanager.google.com *.tagmanager.google.com; child-src blob:; worker-src blob:; object-src none; font-src prod.cz.hcp.novartis.com fonts.gstatic.com *.kaltura.com self data: application:; img-src *.ipredictive.com *.contentsquare.net http: https: data: image: self; frame-src zero-psa-locator.pages.dev www.knotch-cdn.com aim-tag.hcn.health contextweb.com *.contextweb.com bat.bing.com *.doubleclick.net servedby.flashtalking.com di.rlcdn.com self cdnapisec.kaltura.com analytics.google.com *.analytics.google.com google-analytics.com *.google-analytics.com googletagmanager.com *.googletagmanager.com tagmanager.google.com *.tagmanager.google.com; connect-src cdn.pullthrough.tools uatservices.pullthrough.tools code.jquery.com cdn.uat.pullthrough.tools api.ipstack.com api.pullthrough.tools api.uat.pullthrough.tools usim.beprod.us.adakveo.com bam.nr-data.net prod.cz.hcp.novartis.com *.google.com contextweb.com *.contextweb.com bat.bing.com *.doubleclick.net *.googleadservices.net stats.g.doubleclick.net *.contentsquare.net *.kaltura.com ws: self *.googleapis.com *.tiqcdn.com cloudflareinsights.com trc.lhmos.com analytics.google.com *.analytics.google.com google-analytics.com *.google-analytics.com googletagmanager.com *.googletagmanager.com tagmanager.google.com *.tagmanager.google.com; media-src usim.beprod.us.adakveo.com kaltura.com *.kaltura.com blob: self data:; frame-ancestors usim.beprod.us.adakveo.com selfset-cookie: __cf_bm_5G45OVvgHk7QFW5fw_z0D0KtPfL.YZUMQWMPhACMGg-1771951727.1864989-1.0.1.1-wA.8GpRQgA3Wiwyt88tCU4sTre06PeDRGuM.lS_Vb_SKHKVj9GzDKpOZLZsx6o7hHNpV6gNciil6B6Kc4A2GfyGLBzM9Fdhsc8b6eSpj94KQviRmibF.msFRLZ8xVjxA; HttpOnly; Secure; Path/; Domainadakveo.com; ExpiresTue, 24 Feb 2026 17:18:47 GMTvary: Accept-Encodingcf-cache-status: HITCF-RAY: 9d3073d6ed79ff17-PDX !DOCTYPE html>html langen>head>meta charSetutf-8/>meta nameviewport contentinitial-scale1, widthdevice-width/>title>ADAKVEO® (crizanlizumab-tmca) for Sickle Cell Pain Crises/title>meta nametitle contentADAKVEO® (crizanlizumab-tmca) for Sickle Cell Pain Crises/>meta namedescription contentDiscover ADAKVEO, the first and only once-monthly medication to reduce the number of pain crises in sickle cell disease. See full Prescribing & Safety Info./>link relcanonical hrefhttps://us.adakveo.com/>link relalternate hrefLangus-en hrefhttps://us.adakveo.com/>link relalternate hrefLangen-gb hrefhttps://novartis.com/>meta namegoogle-site-verification contentSS4mCRbqVIoqFlA-cPQ40R-ThhbajP16f76rXJrh6m4/>meta namenext-head-count content9/>link relpreconnect hrefhttps://fonts.gstatic.com crossorigin/>link relpreconnect hrefhttps://usim.beprod.us.adakveo.com crossorigin/>meta nameemotion-insertion-point content/>link relicon href/favicon.ico type/>link relpreload hrefhttps://fonts.googleapis.com/css2?familyWork+Sans:wght@400;500;600;700&displayswap asstyle/>link hrefhttps://fonts.googleapis.com/css2?familyWork+Sans:wght@400;500;600;700&displayswap relstylesheet/>link relpreload hrefhttps://fonts.googleapis.com/css2?familyPoppins:wght@400;500;600;700&displayswap asstyle/>link hrefhttps://fonts.googleapis.com/css2?familyPoppins:wght@400;500;600;700&displayswap relstylesheet/>link relpreload hrefhttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/generated_css/variables.css asstyle/>link hrefhttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/generated_css/variables.css relstylesheet/>style data-emotionmui-style 11m6foi v464i3 1uaukoe 1n11r91 1rw1vf5 gwg9c e4jwzf-WYSIWYG vchpmi tiyz5p 1poyntf 1lteid4 778zie mq68gi w6030t 1fby3jt j2uvo2 l1kzfi 1k33q06 j7qwjs 1xggfpg 96ztp4 14en9gs>.mui-style-11m6foi{display:inline;gap:0.25rem;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;text-decoration-skip:none;-webkit-text-decoration:underline;text-decoration:underline;color:rgba(var(--primary_01), 1);font-weight:600;}.mui-style-v464i3{background-color:#fff;color:rgba(0, 0, 0, 0.87);-webkit-transition:box-shadow 300ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:box-shadow 300ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;border-radius:4px;box-shadow:0px 2px 1px -1px rgba(0,0,0,0.2),0px 1px 1px 0px rgba(0,0,0,0.14),0px 1px 3px 0px rgba(0,0,0,0.12);position:relative;-webkit-transition:margin 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:margin 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;overflow-anchor:none;border-radius:0;}.mui-style-v464i3:before{position:absolute;left:0;top:-1px;right:0;height:1px;content:;opacity:1;background-color:rgba(0, 0, 0, 0.12);-webkit-transition:opacity 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms,background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:opacity 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms,background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;}.mui-style-v464i3:first-of-type:before{display:none;}.mui-style-v464i3.Mui-expanded:before{opacity:0;}.mui-style-v464i3.Mui-expanded:first-of-type{margin-top:0;}.mui-style-v464i3.Mui-expanded:last-of-type{margin-bottom:0;}.mui-style-v464i3.Mui-expanded+.mui-style-v464i3.Mui-expanded:before{display:none;}.mui-style-v464i3.Mui-disabled{background-color:rgba(0, 0, 0, 0.12);}.mui-style-v464i3:first-of-type{border-top-left-radius:4px;border-top-right-radius:4px;}.mui-style-v464i3:last-of-type{border-bottom-left-radius:4px;border-bottom-right-radius:4px;}@supports (-ms-ime-align: auto){.mui-style-v464i3:last-of-type{border-bottom-left-radius:0;border-bottom-right-radius:0;}}.mui-style-1uaukoe{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;position:relative;box-sizing:border-box;-webkit-tap-highlight-color:transparent;background-color:transparent;outline:0;border:0;margin:0;border-radius:0;padding:0;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;vertical-align:middle;-moz-appearance:none;-webkit-appearance:none;-webkit-text-decoration:none;text-decoration:none;color:inherit;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;min-height:48px;padding:0px 16px;-webkit-transition:min-height 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms,background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:min-height 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms,background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;}.mui-style-1uaukoe::-moz-focus-inner{border-style:none;}.mui-style-1uaukoe.Mui-disabled{pointer-events:none;cursor:default;}@media print{.mui-style-1uaukoe{-webkit-print-color-adjust:exact;color-adjust:exact;}}.mui-style-1uaukoe.Mui-focusVisible{background-color:rgba(0, 0, 0, 0.12);}.mui-style-1uaukoe.Mui-disabled{opacity:0.38;}.mui-style-1uaukoe:hover:not(.Mui-disabled){cursor:pointer;}.mui-style-1n11r91{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex:1;-webkit-flex-grow:1;-ms-flex-positive:1;flex-grow:1;margin:12px 0;}.mui-style-1rw1vf5{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;}.mui-style-1rw1vf5data-aligncenter{text-align:center;}.mui-style-1rw1vf5data-alignright{text-align:right;}.mui-style-gwg9c{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;gap:1.5rem;}.freeFormdata-aligncenter .mui-style-gwg9c ul,.freeFormdata-aligncenter .mui-style-gwg9c ol{margin-left:auto;margin-right:auto;}.freeFormdata-alignright .mui-style-gwg9c ul,.freeFormdata-alignright .mui-style-gwg9c ol{margin-left:auto;}.mui-style-e4jwzf-WYSIWYG{color:inherit;background:inherit;}.mui-style-e4jwzf-WYSIWYG>*:not(a):not(:last-child){margin-bottom:1.5rem;}.mui-style-e4jwzf-WYSIWYG a:not(.btn){-webkit-text-decoration:underline;text-decoration:underline;}.mui-style-e4jwzf-WYSIWYG p{line-height:145%;}.mui-style-e4jwzf-WYSIWYG .btn{margin:0.5rem;}.mui-style-e4jwzf-WYSIWYG .text-link-01,.mui-style-e4jwzf-WYSIWYG .text-link-02{margin-top:1.5rem;}.mui-style-e4jwzf-WYSIWYG .freeForm__embed{background:rgba(var(--neutral_0), 1);}.mui-style-e4jwzf-WYSIWYG .freeForm__embed .freeForm__img{margin:0 auto;border-radius:0.5rem;}.mui-style-e4jwzf-WYSIWYG .freeForm__embed .lightbox-opener{display:block;margin:0 auto;border-radius:0.5rem;}.mui-style-e4jwzf-WYSIWYG .freeForm__embed .lightbox-opener .freeForm__img{border-radius:0;}.mui-style-e4jwzf-WYSIWYG .kaltura-embed-section{position:absolute;z-index:1;width:100%;height:100%;}.mui-style-e4jwzf-WYSIWYG .kaltura-embed-section img{border-radius:0.5rem;width:100%;}.mui-style-e4jwzf-WYSIWYG .kaltura-embed-section>div{width:100%!important;height:100%!important;}.mui-style-e4jwzf-WYSIWYG .kaltura-image-section>img{width:100%!important;height:auto!important;max-height:304px;border-radius:0.5rem;}@media (min-width:577px){.mui-style-e4jwzf-WYSIWYG .kaltura-image-section>img{max-height:407px;}}@media (min-width:769px){.mui-style-e4jwzf-WYSIWYG .kaltura-image-section>img{max-height:405px;}}@media (min-width:1001px){.mui-style-e4jwzf-WYSIWYG .kaltura-image-section>img{max-height:625px;}}.mui-style-vchpmi{text-align:left;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;color:inherit;line-height:160%;margin-left:0;list-style:disc inside;}.mui-style-vchpmi u,.mui-style-vchpmi strong,.mui-style-vchpmi b,.mui-style-vchpmi span,.mui-style-vchpmi i,.mui-style-vchpmi s,.mui-style-vchpmi strike,.mui-style-vchpmi em,.mui-style-vchpmi mark,.mui-style-vchpmi small,.mui-style-vchpmi ins,.mui-style-vchpmi del,.mui-style-vchpmi code,.mui-style-vchpmi samp,.mui-style-vchpmi kbd,.mui-style-vchpmi cite,.mui-style-vchpmi q,.mui-style-vchpmi blockquote{position:static;}.mui-style-vchpmi li *:first-child:not(ol, ul, li){display:inline;}.mui-style-vchpmi li{margin-bottom:0.5rem;}.mui-style-vchpmi li li{display:-webkit-box;display:-webkit-list-item;display:-ms-list-itembox;display:list-item;}.mui-style-vchpmi li ul,.mui-style-vchpmi li ol{display:block;margin-left:1.5rem;margin-top:0.5rem;}.mui-style-vchpmi li ul li:last-child,.mui-style-vchpmi li ol li:last-child{margin-bottom:0;}.mui-style-tiyz5p{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:flex-start;justify-content:flex-start;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;gap:1.5rem;}.mui-style-1poyntf img{border-radius:0.5rem;}.mui-style-1lteid4{height:0.125rem;}.mui-style-778zie{-webkit-transition:left 0.25s ease;transition:left 0.25s ease;z-index:950;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;border:1px solid rgba(var(--core_neutral_30), 1);background-color:rgba(var(--neutral_0), 1);box-shadow:0px 4px 12px rgba(0, 0, 0, 0.4);position:fixed;border-radius:0.5rem;padding:1rem;overflow-y:auto;bottom:2rem;right:2rem;left:2rem;max-height:calc(100vh - 5rem - 8.5rem);}.with-secondary-option_2 .mui-style-778zie{max-height:calc(100vh - 5rem - 8.5rem);}.with-secondary-option_1 .mui-style-778zie{bottom:calc(2rem + 8.5rem);}@media (min-width:577px){.mui-style-778zie{padding:1.5rem 3rem;}}@media (min-width: 0) and (max-width: 640px){.with-secondary-option_1 .mui-style-778zie{max-height:calc(100vh - 5rem - 8.5rem - 1rem);}}@media (min-width:769px){.mui-style-778zie{max-height:calc(100vh - 4rem);}.with-secondary-option_1 .mui-style-778zie{left:calc(11.5rem + 2rem);bottom:2rem;padding:1.5rem 3rem;}.collapsed .mui-style-778zie{left:calc(6.5rem + 2rem);}}@media (min-width:1001px){.with-secondary-option_1 .mui-style-778zie{left:calc(15rem + 2rem);}.with-secondary-option_2 .mui-style-778zie{left:calc(15rem + 2rem);padding:1.5rem 3rem;}.collapsed .mui-style-778zie{left:calc(6.5rem + 2rem);}}.mui-style-mq68gi{-webkit-flex:1;-ms-flex:1;flex:1;display:none;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;}@media (min-width:577px){.mui-style-mq68gi{-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;gap:1.5rem;}}.mui-style-w6030t{-webkit-flex:1;-ms-flex:1;flex:1;}.mui-style-w6030t .MuiBox-root>*:not(a):not(:last-child){margin-bottom:0.75rem;}.mui-style-1fby3jt{color:rgba(var(--primary_01), 1);font-weight:700;margin-bottom:0.75rem;}.mui-style-j2uvo2{color:rgba(var(--primary_01), 1);font-weight:700;margin-bottom:0.75rem;font-family:var(--font_primary);-webkit-align-self:center;-ms-flex-item-align:center;align-self:center;text-align:center;margin:0;}.mui-style-l1kzfi{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;position:relative;box-sizing:border-box;-webkit-tap-highlight-color:transparent;background-color:transparent;outline:0;border:0;margin:0;border-radius:0;padding:0;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;vertical-align:middle;-moz-appearance:none;-webkit-appearance:none;-webkit-text-decoration:none;text-decoration:none;color:inherit;text-align:center;-webkit-flex:0 0 auto;-ms-flex:0 0 auto;flex:0 0 auto;font-size:1.5rem;padding:8px;border-radius:50%;overflow:visible;color:rgba(0, 0, 0, 0.54);-webkit-transition:background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;background-color:rgba(var(--primary_01), 1);color:rgba(var(--neutral_0), 1);border-radius:0.5rem;height:2rem;width:2rem;right:0.75rem;top:0.75rem;position:absolute;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}.mui-style-l1kzfi::-moz-focus-inner{border-style:none;}.mui-style-l1kzfi.Mui-disabled{pointer-events:none;cursor:default;}@media print{.mui-style-l1kzfi{-webkit-print-color-adjust:exact;color-adjust:exact;}}.mui-style-l1kzfi:hover{background-color:rgba(0, 0, 0, 0.04);}@media (hover: none){.mui-style-l1kzfi:hover{background-color:transparent;}}.mui-style-l1kzfi.Mui-disabled{background-color:transparent;color:rgba(0, 0, 0, 0.26);}.mui-style-l1kzfi:focus{outline:0.125rem solid rgba(var(--info_light), 1);}.mui-style-l1kzfi:hover{background-color:rgba(var(--primary_01), 1);color:rgba(var(--neutral_0), 1);}.mui-style-1k33q06{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:1.25rem;}.mui-style-j7qwjs{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;}.mui-style-1xggfpg{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:flex-start;-webkit-box-align:flex-start;-ms-flex-align:flex-start;align-items:flex-start;}.mui-style-1xggfpg div{gap:1rem;}@media (max-width:576.95px){.mui-style-1xggfpg div{gap:0.5rem;}}.mui-style-96ztp4{color:rgba(var(--neutral_80), 1);font-size:0.75rem;line-height:130%;letter-spacing:0.01em;font-weight:400;padding:20px 0 0.25rem;}@media (max-width:576.95px){.mui-style-96ztp4{padding:1rem 0 0.25rem;}}.mui-style-14en9gs{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;position:relative;box-sizing:border-box;-webkit-tap-highlight-color:transparent;background-color:transparent;outline:0;border:0;margin:0;border-radius:0;padding:0;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;vertical-align:middle;-moz-appearance:none;-webkit-appearance:none;-webkit-text-decoration:none;text-decoration:none;color:inherit;position:relative;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;gap:0.75rem;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;min-height:56px;box-sizing:border-box;box-shadow:0px 4px 4px rgba(0, 0, 0, 0.25);border:0;border-radius:3rem;padding:0.25rem 1.5rem;font-weight:600;font-size:0.938rem;font-family:var(--font_primary);line-height:115%;text-align:center;color:rgba(var(--neutral_0), 1);-webkit-transition:box-shadow .2s,opacity .2s;transition:box-shadow .2s,opacity .2s;cursor:pointer;background-color:rgba(var(--primary_01), 1);}.mui-style-14en9gs::-moz-focus-inner{border-style:none;}.mui-style-14en9gs.Mui-disabled{pointer-events:none;cursor:default;}@media print{.mui-style-14en9gs{-webkit-print-color-adjust:exact;color-adjust:exact;}}.mui-style-14en9gs:before,.mui-style-14en9gs:after{opacity:0;position:absolute;content:;width:100%;height:100%;border-radius:3rem;-webkit-transition:300ms;transition:300ms;}.mui-style-14en9gs:before{border:0.25rem solid #fff;}.mui-style-14en9gs:after{width:calc(100% + 0.25rem);height:calc(100% + 0.25rem);border:0.25rem solid rgba(var(--info_light), 1);}.mui-style-14en9gs:hover:not(:active){opacity:0.88;}.mui-style-14en9gs:focus:not(:active){box-shadow:none;}.mui-style-14en9gs:focus:not(:active):before,.mui-style-14en9gs:focus:not(:active):after{opacity:1;}.mui-style-14en9gs.Mui-disabled{opacity:0.48;}.mui-style-14en9gs.small{min-height:3rem;font-size:0.75rem;}.mui-style-14en9gs.large{min-height:4rem;font-size:0.938rem;}.mui-style-14en9gs.medium{min-height:56px;font-size:0.938rem;}/style>link relpreload href/_next/static/css/816758210c29699d.css asstyle/>link relstylesheet href/_next/static/css/816758210c29699d.css data-n-g/>noscript data-n-css>/noscript>script defer nomodule src/_next/static/chunks/polyfills-42372ed130431b0a.js>/script>script src/vendor/scripts/jquery-3.6.0.min.js defer data-nscriptbeforeInteractive>/script>script src/vendor/scripts/swiper-bundle.min.js defer data-nscriptbeforeInteractive>/script>script src/_next/static/chunks/webpack-36d12a75f0098f30.js defer>/script>script src/_next/static/chunks/framework-63d16ff2f5e08230.js defer>/script>script src/_next/static/chunks/main-4afe96d8b6df2098.js defer>/script>script src/_next/static/chunks/pages/_app-03d4f45b74eecfaa.js defer>/script>script src/_next/static/chunks/252f366e-ad5c1b8c778178ac.js defer>/script>script src/_next/static/chunks/7d0bf13e-005fa93ad2ab3e9d.js defer>/script>script src/_next/static/chunks/382-df226f41265fc1fb.js defer>/script>script src/_next/static/chunks/554-3f2fa2ec600c38f8.js defer>/script>script src/_next/static/chunks/pages/index-6f835e1e92a4f29a.js defer>/script>script src/_next/static/NalTJwMYG2qxqZ3I_yxAX/_buildManifest.js defer>/script>script src/_next/static/NalTJwMYG2qxqZ3I_yxAX/_ssgManifest.js defer>/script>/head>body classwith-secondary-option_2>div id__next>div idlayout>a classvisually-hidden mui-style-11m6foi href#main-content stylepointer-events:auto>Skip to main content/a>div classMuiPaper-root MuiPaper-elevation MuiPaper-rounded MuiPaper-elevation1 MuiAccordion-root MuiAccordion-rounded secondary-alt mui-style-v464i3>div classsecondary-alt__header>div classsecondary-alt__top>a classsecondary-alt__logo mui-style-11m6foi href/ stylepointer-events:auto>img srchttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/secondary_navigation/logo_full/adakveo-logo.png altADAKVEO® (crizanlizumab-tmca) logo/>/a>div classsecondary-alt__burger>div classMuiButtonBase-root MuiAccordionSummary-root mui-style-1uaukoe tabindex0 rolebutton aria-expandedfalse aria-haspopuptrue aria-labelMenu>div classMuiAccordionSummary-content mui-style-1n11r91>div classburger-menu-icon>div classburger-menu-icon__bar>/div>/div>/div>/div>/div>/div>/div>/div>header classheader >div classnavigation-primary primary_01-bg navigation-primary--without-toogle>div classnavigation-primary__info>span classnavigation-primary__text neutral_0-c>This site is for US residents only./span>/div>div classnavigation-primary__nav styleheight:24px>ul classnavigation-primary__links>li classnavigation-primary__links-item >a hrefhttps://www.novartis.com/us-en/sites/novartis_us/files/adakveo.pdf classnavigation-primary__link neutral_0-c mui-style-11m6foi target_blank data-content-typeutility relnoreferrer stylepointer-events:auto>Prescribing Information/a>/li>/ul>/div>/div>/header>div classwrapper>div classportal-violator>/div>main idmain-content>div>div classportal-hero-violator>/div>div>div classcontainer>div classrow>div classcol-10 offset-1>div classpt-7 pb-1 data-module-sizefull>div classfreeForm mui-style-1rw1vf5 data-alignleft>div classmui-style-gwg9c>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>h4 classheading-01>span classprimary_01-c backgroundprimary_01-b>ADAKVEO/span>br/> /h4>h6 classheading-03>ADAKVEO is a 30-minute IV infusion given once per month after your second dosesup>1/sup>/h6>div classfreeForm__embed>picture>source media(max-width:576px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/2023-10/adakveo_iv_infusion_timeline_mobile.svg width400 height134/>source media(max-width:768px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/2023-10/adakveo_iv_infusion_timeline_desktop.svg width628 height211/>source media(max-width:1000px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/2023-10/adakveo_iv_infusion_timeline_desktop.svg width688 height231/>img srchttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/2023-10/adakveo_iv_infusion_timeline_desktop.svg loadinglazy altADAKVEO dosing schedule classfreeForm__img width744 height250/>/picture>/div>ul classmui-style-vchpmi>li>p classparagraph-01>You will receive your first infusion, and then a second infusion 2 weeks latersup>1/sup>/p>/li>li>p classparagraph-01>After that, you will be given an IV infusion every 4 weekssup>1/sup>/p>/li>li>p classparagraph-01>If you miss an appointment for your infusion, contact your doctor or health care provider as soon as possible to reschedule/p>/li>li>p classparagraph-01>Your health care provider may also prescribe other treatments for you to take during treatment with ADAKVEO/p>/li>li>p classparagraph-01>Do not stop receiving ADAKVEO unless your health care provider tells you to/p>/li>/ul>p classdisclaimers-notes>IV, intravenous./p>/div>/div>/div>/div>/div>/div>/div>/div>div>div classpt-4 pb-0>section classhero hero__H130 primary_01-bg data-text-aligncenter data-module-sizeeight-columns data-only-imagefalse>div classcontainer>div classrow>div classcol-10 offset-1 col-md-8 offset-md-2>div classhero__section>h1 classtitle-01>span classMuiBox-root mui-style-e4jwzf-WYSIWYG>span classneutral_0-c>strong>Novartis Patient Support™/strong>/span>/span>/h1>div classbutton__container>div classMuiBox-root mui-style-tiyz5p>/div>/div>/div>/div>/div>/div>/section>div classcontainer>/div>/div>/div>div>div classcontainer>div classrow>div classcol-10 offset-1>div classpt-1 pb-2 data-module-sizefull>div classfreeForm mui-style-1rw1vf5 data-alignleft>div classmui-style-gwg9c>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>p classparagraph-01>span classneutral_70-c>strong>Novartis Patient Support is a program to help you start, stay, and save on your ADAKVEO treatment. To learn more, call 1-800-282-7630./strong> /span>/p>h5 classheading-02>span classprimary_03-c backgroundprimary_03-b>Universal Co-pay Program/span>/h5>/div>/div>/div>/div>/div>/div>/div>/div>div>div classcontainer>div classrow>div classcol-10 offset-1 >div classfeaturedContentCards__AB300 pt-7 pb-3 data-module-sizefull>div classfeaturedContentCard data-content-aligncenter data-alignasset-left>div classfeaturedContentCard__content>figure classfeaturedContentCard__figure>div classfeaturedContentCard__asset>picture classmui-style-1poyntf>source media(max-width: 576px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/webp/public/styles/common_width_400/public/2024-09/co-pay-image.png.webp?itokvM-MVPGf width400 height264 typeimage/webp/>source media(max-width: 768px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/webp/public/styles/single_featured_content_card_without_content_width_552/public/2024-09/co-pay-image.png.webp?itokLSARIY4R width552 height364 typeimage/webp/>source media(max-width: 1000px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/webp/public/styles/single_featured_content_card_without_content_width_608/public/2024-09/co-pay-image.png.webp?itok854xPNYd width608 height401 typeimage/webp/>source media(min-width: 1000px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/webp/public/styles/single_featured_content_card_without_content_width_744/public/2024-09/co-pay-image.png.webp?itokt-vwrwXX width744 height490 typeimage/webp/>source media(max-width: 576px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/common_width_400/public/2024-09/co-pay-image.png?itoksdwCaZEX width400 height264/>source media(max-width: 768px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/single_featured_content_card_without_content_width_552/public/2024-09/co-pay-image.png?itok8seUU3su width552 height364/>source media(max-width: 1000px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/single_featured_content_card_without_content_width_608/public/2024-09/co-pay-image.png?itokufNkrIRl width608 height401/>source media(min-width: 1000px) srcSethttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/single_featured_content_card_without_content_width_744/public/2024-09/co-pay-image.png?itokYTWyFZHv width744 height490/>img srchttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/single_featured_content_card_without_content_width_744/public/2024-09/co-pay-image.png?itokYTWyFZHv width744 height490 altNovartis Universal Co-Pay Card loadinglazy/>/picture>/div>/figure>div classfeaturedContentCard__text>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>h5 classfeaturedContentCard__subtitle>p>span classprimary_02-c backgroundprimary_02-b>strong>SAVE WITH THE UNIVERSAL CO-PAY PROGRAM/strong>/span>/p>/h5>/div>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>div classfeaturedContentCard__body>p>You may be eligible for immediate co-pay savings on your next prescription of ADAKVEO./p>p> /p>ul classmui-style-vchpmi>li>p classparagraph-01>Eligible patients with private insurance may pay as little as $0 for your ADAKVEO treatment each month/p>/li>li>p classparagraph-01>Novartis will pay the remaining co-pay, up to $15,000 per calendar yearsup>*/sup>/p>/li>/ul>/div>/div>/div>/div>/div>/div>/div>/div>/div>/div>div>div classcontainer>div classrow>div classcol-10 offset-1>div classpt-2 pb-7 data-module-sizefull>div classfreeForm mui-style-1rw1vf5 data-alignleft>div classmui-style-gwg9c>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>p classdisclaimers-notes>*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice./p>p classdisclaimers-notes>For full Terms and Conditions, visit a hrefhttps://copay.novartisoncology.com/ classmui-style-11m6foi target_blank data-content-typelink stylepointer-events:auto>span classprimary_01-c backgroundprimary_01-b>Copay.NovartisOncology.com/span>/a> or call 1-877-577-7756./p>/div>/div>/div>/div>/div>/div>/div>/div>/div>/main>div classmui-style-1lteid4>/div>section classparagraph-03 mui-style-778zie roledialog aria-labelImportant Safety Information overview>div idISI classmui-style-mq68gi>div classmui-style-w6030t>h2 classmui-style-1fby3jt>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>strong>Important Safety Information/strong>/div>/h2>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>p>strong>What is the most important information I should know about ADAKVEO?/strong>/p>p>strong>ADAKVEO may cause serious side effects, including infusion-related reactions. /strong>br/>br/>strong>Infusion-related reactions./strong> Infusion-related reactions may happen during or within 24 hours of receiving an infusion of ADAKVEO. Infusion-related reactions may cause pain in different areas of your body.../p>/div>/div>div classmui-style-w6030t>h2 classmui-style-1fby3jt>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>strong>Approved Use/strong>/div>/h2>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>p>strong>What is ADAKVEOsup>®/sup> (crizanlizumab-tmca)?/strong>/p>p>ADAKVEO is a prescription medicine used in people 16 years of age and older who have sickle cell disease to help reduce how often painful crises happen./p>p>It is not known if ADAKVEO is safe and effective in children under 16 years of age.../p>/div>/div>/div>a href# classmui-style-j2uvo2>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>strong>Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE/strong>/div>/a>button classMuiButtonBase-root MuiIconButton-root MuiIconButton-sizeMedium mui-style-l1kzfi tabindex0 typebutton aria-labelCollapse ISI aria-expandedtrue aria-controlsISI>svg classMuiSvgIcon-root MuiSvgIcon-fontSizeSmall mui-style-1k33q06 focusablefalse aria-hiddentrue viewBox0 0 24 24 data-testidCloseIcon>path dM19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z>/path>/svg>/button>/section>div>div classportal-hero-violator>/div>div>div classcontainer>div classrow>div classcol-10 offset-1>div classfootnote footnote__R770 pt-7 pb-7>div classmui-style-j7qwjs>div classmui-style-1xggfpg>div classMuiBox-root mui-style-tiyz5p>/div>/div>div classmui-style-96ztp4>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>strong>Reference: 1./strong> Adakveo. Prescribing information. Novartis Pharmaceuticals Corp./div>/div>/div>/div>/div>/div>/div>/div>/div>footer classfooter>div classfooter__top>ul classfooter__list>li classfooter__list-item>a classfooter__list-link mui-style-11m6foi hrefhttps://medinfo.novartispharmaceuticals.com/medinfo/s/ target_blank data-content-typefooter relnoreferrer stylepointer-events:auto>Medical Information/a>/li>li classfooter__list-item>a classfooter__list-link mui-style-11m6foi hrefhttps://www.novartis.com/us-en/contact-non-hcp target_blank data-content-typefooter relnoreferrer stylepointer-events:auto>Contact Us/a>/li>li classfooter__list-item>a classfooter__list-link mui-style-11m6foi hrefhttps://www.novartis.com/about target_blank data-content-typefooter relnoreferrer stylepointer-events:auto>Non-US Residents/a>/li>/ul>/div>div classfooter__bottom>figure classfooter__logo>a hrefhttps://www.novartis.com/us-en/about target_blank data-content-typefooter stylepointer-events:auto classmui-style-11m6foi>img srchttps://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/banner_full_width_144/public/footer/logo/logo_0%20%281%29.png?itokXQBpvzns altNovartis logo loadinglazy/>/a>/figure>div classfooter__trademark>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>p>ADAKVEO is a registered trademark of Novartis AG./p>/div>/div>div classfooter__text>div classfooter__links>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>p>Use of website is governed by the a hrefhttps://www.novartis.com/us-en/terms-use classmui-style-11m6foi target_blank data-content-typelink stylepointer-events:auto>Terms of Use/a> and a hrefhttps://www.novartis.com/us-en/privacy classmui-style-11m6foi target_blank data-content-typelink stylepointer-events:auto>Privacy Policy/a>. /p>p>a hrefhttps://www.novartis.com/us-en/privacy/consumer-health classmui-style-11m6foi titleTerms of use target_blank data-content-typelink stylepointer-events:auto>Consumer Health Privacy Policy/a>br/> /p>/div>/div>div classfooter__copyright>div classMuiBox-root mui-style-e4jwzf-WYSIWYG>p>br/>Copyright © 2024 a hrefhttps://www.novartis.com/us-en/about classmui-style-11m6foi target_blank data-content-typelink stylepointer-events:auto>Novartis Pharmaceuticals Corporation/a>. All rights reserved./p>/div>/div>/div>div classfooter__info>div classfooter__social>/div>p classfooter__fuseCode>8/24 FA-11246840/p>/div>/div>/footer>/div>/div>div classcontainer>div classrow>div classcol-12 d-flex justify-content-end>div classbutton__container btn-back-top>button classMuiButtonBase-root btn small mui-style-14en9gs tabindex0 typebutton target_self data-controlBackToTop data-content-typebutton>Back to top/button>/div>/div>/div>/div>/div>script id__NEXT_DATA__ typeapplication/json>{props:{pageProps:{multiIndication:{title:Change Indication,backgroundColor:neutral_05,icon:{src:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/icons/2023-03/close_nav.svg,srcSet:,sizes:,alt:Close icon,width:14,height:14}},toTop:{isEnabled:true,backgroundColor:primary_01,textColor:neutral_0},violatorConfig:{isVisible:false,backgroundColor:primary_01,textColor:neutral_0,title:A Note from Novartis on Covid-19!,underTitle:false,body:\u003cp\u003eFor additional help, including samples, please contact your Novartis representative!!!!\u0026nbsp;\u003c/p\u003e\n,shortTitle:Covid-19 Information,displayShortTitle:true,linkUrl:http://novartishcp.com,linkTarget:_blank,linkTitle:null},ISIConfigGeneral:{version:2,isEnabled:true,ISITitle:\u003cstrong\u003eImportant Safety Information\u003c/strong\u003e,ISITitleTag:h2,shortISIBody:\u003cp\u003e\u003cstrong\u003eWhat is the most important information I should know about ADAKVEO?\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eADAKVEO may cause serious side effects, including infusion-related reactions.\u0026nbsp;\u003c/strong\u003e\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eInfusion-related reactions.\u003c/strong\u003e\u0026nbsp;Infusion-related reactions may happen during or within 24\u0026nbsp;hours of receiving an infusion of ADAKVEO. Infusion-related reactions may cause pain in different areas of your body...\u003c/p\u003e,fullISIBody:\u003cp\u003e\u003cstrong\u003eWhat is the most important information I should know about ADAKVEO?\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eADAKVEO may cause serious side effects, including infusion-related reactions.\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eInfusion-related reactions.\u003c/strong\u003e\u0026nbsp;Infusion-related reactions may happen during or within 24\u0026nbsp;hours of receiving an infusion of ADAKVEO. Infusion-related reactions may cause pain in different areas of your body. Your health care provider may slow down, temporarily stop, or completely stop your infusion with ADAKVEO if you have an infusion-related reaction. You may continue to receive ADAKVEO at a slower infusion rate, and your health care provider may give you certain medicines before your infusion to lower your risk of getting an infusion-related reaction. Your health care provider should monitor you for signs and symptoms of infusion-related reactions and treat your symptoms as needed. Tell your health care provider right away if you get any of the following signs and symptoms of an infusion-related reaction:\u003c/p\u003e\u003cul\u003e\u003cli\u003epain in various locations\u003c/li\u003e\u003cli\u003eheadache\u003c/li\u003e\u003cli\u003efever\u003c/li\u003e\u003cli\u003echills or shivering\u003c/li\u003e\u003cli\u003enausea\u003c/li\u003e\u003cli\u003evomiting\u003c/li\u003e\u003cli\u003ediarrhea\u003c/li\u003e\u003cli\u003etiredness\u003c/li\u003e\u003cli\u003edizziness\u003c/li\u003e\u003cli\u003esweating\u003c/li\u003e\u003cli\u003ehives\u003c/li\u003e\u003cli\u003eitching\u003c/li\u003e\u003cli\u003eshortness of breath or wheezing\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eADAKVEO may interfere with a blood test.\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eTell your health care provider that you are receiving ADAKVEO before having any blood tests. ADAKVEO may interfere with a laboratory test to measure your platelet counts.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBefore receiving ADAKVEO, tell your health care provider about all of your medical conditions, including if you\u003c/strong\u003e\u003c/p\u003e\u003cul\u003e\u003cli\u003eare pregnant or plan to become pregnant. ADAKVEO may harm your unborn baby. Talk to your health care provider about the possible risk to your unborn baby if you take ADAKVEO during pregnancy\u003c/li\u003e\u003cli\u003eare breastfeeding or plan to breastfeed. It is not known if ADAKVEO passes into your breast milk. You and your health care provider should decide the best way to feed your baby during treatment with ADAKVEO\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u003cstrong\u003eTell your health care provider about all of the medicines you take\u003c/strong\u003e, including prescription and over-the-counter medicines, vitamins, and herbal supplements.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eThe most common side effects of ADAKVEO include:\u003c/strong\u003e\u003c/p\u003e\u003cul\u003e\u003cli\u003eheadache\u003c/li\u003e\u003cli\u003ejoint pain\u003c/li\u003e\u003cli\u003enausea\u003c/li\u003e\u003cli\u003eback pain\u003c/li\u003e\u003cli\u003efatigue\u003c/li\u003e\u003cli\u003estomach pain\u003c/li\u003e\u003cli\u003efever\u003c/li\u003e\u003cli\u003ediarrhea\u003c/li\u003e\u003cli\u003evomiting\u003c/li\u003e\u003cli\u003ethroat pain\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eThese are not all of the possible side effects of ADAKVEO. For more information, ask your health care provider or pharmacist.\u003c/p\u003e\u003cp\u003eCall your doctor for medical advice about side effects.\u003c/p\u003e\u003cp\u003eYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit\u0026nbsp;\u003ca href\https://fda.gov/medwatch\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003ewww.fda.gov/medwatch\u003c/span\u003e\u003c/a\u003e, or call\u0026nbsp;\u003ca href\tel: 1-800-332-1088\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003e1-800-FDA-1088\u003c/span\u003e\u003c/a\u003e.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003ePlease see accompanying full\u0026nbsp;\u003c/strong\u003e\u003ca href\https://www.novartis.com/us-en/sites/novartis_us/files/adakveo.pdf\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003e\u003cstrong\u003ePrescribing Information\u003c/strong\u003e\u003c/span\u003e\u003c/a\u003e\u003cstrong\u003e, including\u0026nbsp;\u003c/strong\u003e\u003ca href\https://www.novartis.com/us-en/sites/novartis_us/files/adakveo.pdf#page11\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003e\u003cstrong\u003ePatient Information\u003c/strong\u003e\u003c/span\u003e\u003c/a\u003e\u003cstrong\u003e.\u003c/strong\u003e\u003c/p\u003e,genericPromptFull:\u003cstrong\u003eClick or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE\u003c/strong\u003e,genericPromptMobile:\u003cstrong\u003eTap to see IMPORTANT SAFETY INFORMATION AND APPROVED USE\u003c/strong\u003e,isEnableIndication:true,indicationTitle:\u003cstrong\u003eApproved Use\u003c/strong\u003e,indicationTitleTag:h2,shortIndicationBody:\u003cp\u003e\u003cstrong\u003eWhat is ADAKVEO\u003csup\u003e®\u003c/sup\u003e\u0026nbsp;(crizanlizumab-tmca)?\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eADAKVEO is a prescription medicine used in people 16 years of age and older who have sickle cell disease to help reduce how often painful crises happen.\u003c/p\u003e\u003cp\u003eIt is not known if ADAKVEO is safe and effective in children under 16 years of age...\u003c/p\u003e,fullIndicationBody:\u003cp\u003e\u003cstrong\u003eWhat is ADAKVEO\u003csup\u003e®\u003c/sup\u003e\u0026nbsp;(crizanlizumab-tmca)?\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eADAKVEO is a prescription medicine used in people 16 years of age and older who have sickle cell disease to help reduce how often painful crises happen.\u003c/p\u003e\u003cp\u003eIt is not known if ADAKVEO is safe and effective in children under 16 years of age.\u003c/p\u003e,ISIFontSize:paragraph-03},errorConfig:{background:primary_01,titleColor:neutral_20,bodyColor:core_neutral_05,errors:{403:{title:Were sorry - you do not have access.,description:Not to worry. You can head over to our homepage or check out some of our content.,button:{id:94ed4a51-c81b-4293-8be4-f1e54c1d4489,label:Back to Homepage,link:/,target:_self,buttonStyle:tertiary,buttonColor:primary_02,textColor:neutral_0,buttonSize:large},errorFuseCode:{fuseCodeAlignment:right,fuseCodeDisplay:false,fuseCodeText:}},404:{title:The website you are looking for is unavailable.,description:The URL may have been incorrectly typed or the page may have been moved, deleted, or incorporated into another part of the website.,button:{id:e6cee870-46d1-48c3-b0fb-198b5c1ee808,label:Back to Homepage,link:/,target:_blank,buttonStyle:tertiary,buttonColor:primary_02,textColor:neutral_0,buttonSize:responsive},errorFuseCode:{fuseCodeAlignment:right,fuseCodeDisplay:false,fuseCodeText:}},500:{title:Were sorry - it looks like there is an issue,description:Not to worry. You can head over to our homepage or check out some of our content.,button:{id:30e66d1c-d5c2-443e-a709-33c6be101597,label:Back to Homepage,link:/,target:_blank,buttonStyle:tertiary,buttonColor:neutral_20,textColor:primary_01,buttonSize:large},errorFuseCode:{fuseCodeAlignment:right,fuseCodeDisplay:false,fuseCodeText:}}}},fonts:{font_primary:{name:Work Sans,url:https://fonts.googleapis.com/css2?familyWork+Sans:wght@400;500;600;700\u0026displayswap},font_secondary:{name:Poppins,url:https://fonts.googleapis.com/css2?familyPoppins:wght@400;500;600;700\u0026displayswap}},variables:{css:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/generated_css/variables.css},footer:{config:{logoAltText:Novartis logo,logoUrl:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/banner_full_width_144/public/footer/logo/logo_0%20%281%29.png?itokXQBpvzns,logoLinkUrl:https://www.novartis.com/us-en/about,logoLinkTarget:_blank,copyright:\u003cp\u003e\u003cbr\u003eCopyright © 2024\u0026nbsp;\u003ca href\https://www.novartis.com/us-en/about\ target\_blank\ rel\noopener\\u003eNovartis Pharmaceuticals Corporation\u003c/a\u003e. All rights reserved.\u003c/p\u003e,trademark:\u003cp\u003eADAKVEO is a registered trademark of Novartis AG.\u003c/p\u003e,TOUText:\u003cp\u003eUse of website is governed by the \u003ca href\https://www.novartis.com/us-en/terms-use\ target\_blank\ rel\noopener\\u003eTerms of Use\u003c/a\u003e and \u003ca href\https://www.novartis.com/us-en/privacy\ target\_blank\ rel\noopener\\u003ePrivacy Policy\u003c/a\u003e.\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003ca href\https://www.novartis.com/us-en/privacy/consumer-health\ target\_blank\ title\Terms of use\\u003eConsumer Health Privacy Policy\u003c/a\u003e\u003cbr\u003e\u0026nbsp;\u003c/p\u003e,HCPNotice:null,fuseCodeText:8/24 FA-11246840,fuseCodeDisplay:true},menu:{description:null,enabled:true,expanded:false,menu_name:footer,meta:{entity_id:366},options:{attributes:{target:_blank,class:},external:true},parent:,provider:menu_link_content,route:{name:,parameters:},title:Medical Information,url:https://medinfo.novartispharmaceuticals.com/medinfo/s/,weight:-49,field_visibility_path:null,label:Medical Information,link:https://medinfo.novartispharmaceuticals.com/medinfo/s/,target:_blank,visibilityPath:null},{description:test,enabled:true,expanded:false,menu_name:footer,meta:{entity_id:211},options:{attributes:{target:_blank,class:},external:true},parent:,provider:menu_link_content,route:{name:,parameters:},title:Contact Us,url:https://www.novartis.com/us-en/contact-non-hcp,weight:-48,field_visibility_path:null,label:Contact Us,link:https://www.novartis.com/us-en/contact-non-hcp,target:_blank,visibilityPath:null},{description:null,enabled:true,expanded:false,menu_name:footer,meta:{entity_id:216},options:{attributes:{target:_blank,class:},external:true},parent:,provider:menu_link_content,route:{name:,parameters:},title:Non-US Residents,url:https://www.novartis.com/about,weight:-47,field_visibility_path:null,label:Non-US Residents,link:https://www.novartis.com/about,target:_blank,visibilityPath:null},social:{title:Follow {Drug Name} on social media,iconList:}},navPrimary:{config:{backgroundColor:primary_01,showToggleLink:false,toggleLink:right,toggleLinkTextColor:core_neutral_30,leftSideText:Patients ,rightSideText:HCPs,text:This site is for US residents only.,textColor:neutral_0,textColorDisable:core_neutral_05,collapsed:true,toggleUri:https://cosentyxhcp.com,toggleUriTarget:_blank},menu:{id:menu_link_content:a236e922-0f0f-49a1-b0f0-a08027941b94,attributes:{target:_blank,class:},link:https://www.novartis.com/us-en/sites/novartis_us/files/adakveo.pdf,title:Prescribing Information,weight:-49,description:null,parent:,textColor:neutral_0,visibilityPath:null}},navSecondary:{config:{type:option_2,logo:{src:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/secondary_navigation/logo_full/adakveo-logo.png,alt:ADAKVEO® (crizanlizumab-tmca) logo},logoReduced:{src:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/secondary_navigation/logo_reduced/adakveo-logo.png,alt:ADAKVEO® Logo},button:null,quickLinks:{title:null,links:},fusecode:{fuseCodeAlignment:center}},menu:},siteMap:{fuseCodeConfig:{fuseCodeAlignment:right,fuseCodeDisplay:false,fuseCodeText:}},gtm:{gtmId:GTM-MNKRJV8D,gtmStatus:true,gtmDataLayerStatus:true},tealiumUri:null,externalLink:{whiteList:novartis.us,novartis.com,copay.novartisoncology.com/,adakveo.com,tel: 1-800-332-1088,medinfo.novartispharmaceuticals.com/medinfor/s/,,novartisList:null,externalModalConfig:{modalConfig:{id:external,title:You are about to leave ADAKVEO.com,titleTag:h1,body:You are about to leave a Novartis site and continue to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation.,bodyColor:neutral_60,isShowUnderTitle:true,fuseCode:{}},continueButtonConfig:{id:external_link_disclaimer,buttonSize:large,buttonStyle:primary,buttonColor:primary_01,label:Continue to External Site,textColor:neutral_0,target:_blank,icon:{placement:left}}},novartisModalConfig:{modalConfig:{id:novartis,title:You are about to leave ADAKVEO.com,titleTag:h1,body:You are now being directed to another Novartis website.,bodyColor:neutral_60,isShowUnderTitle:true,fuseCode:{}},continueButtonConfig:{id:external_link_disclaimer,buttonSize:large,buttonStyle:primary,buttonColor:primary_01,label:Continue to External Site,textColor:neutral_0,target:_blank,icon:{placement:left}}}},PILink:{PIModalConfig:null},modalFirstVisitConfig:null,cookieManagementOverlay:null,host:https://usim.beprod.us.adakveo.com,requestHost:www.us.adakveo.com,themeAdjustments:{modal_opacity:alpha_70},favicon:{url:,type:},googleMapApiKey:AIzaSyA8wrutWwRnxZD2tJz1nZCEGGxH0KB3A3c,knotchSettings:{},type:node--landing_page_lb,page:{id:86,revisionId:5781,title:ADAKVEO® (crizanlizumab-tmca) for Sickle Cell Pain Crises,meta:{tag:meta,attributes:{name:title,content:ADAKVEO® (crizanlizumab-tmca) for Sickle Cell Pain Crises}},{tag:meta,attributes:{name:description,content:Discover ADAKVEO, the first and only once-monthly medication to reduce the number of pain crises in sickle cell disease. See full Prescribing \u0026 Safety Info.}},{tag:link,attributes:{rel:canonical,href:https://us.adakveo.com}},{tag:link,attributes:{rel:alternate,hrefLang:us-en,href:https://us.adakveo.com}},{tag:link,attributes:{rel:alternate,hrefLang:en-gb,href:https://novartis.com}},{tag:meta,attributes:{name:google-site-verification,content:SS4mCRbqVIoqFlA-cPQ40R-ThhbajP16f76rXJrh6m4}},bgColor:bg_color,pageGtm:{brand:adakveo,type:dtc,category:branded,ml_id:8/24 FA-11246840,indication:sickle cell disease,section:home,subsection:,content_group:single,page_name:adakveo:dtc:branded:home}},layout:{id:layout_onecol,title:column,components:{id:86ce0381-b059-4eb7-8cbd-122ba2e77069,type:free_form,weight:0,content:{id:{value:2866},uuid:{value:ec52e749-fb40-4a0d-afcf-3138ffd6cf50},type:{target_id:free_form,target_type:block_content_type,target_uuid:5c316907-21d0-475c-ae52-1d1709337955},top_vertical_spacing:{value:7},bottom_vertical_spacing:{value:1},field_align:{value:left},field_body:{value:\u003ch4 class\heading-01\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003eADAKVEO\u003c/span\u003e\u003cbr\u003e\u0026nbsp;\u003c/h4\u003e\u003ch6 class\heading-03\\u003eADAKVEO is a 30-minute IV infusion given once per month after your second dose\u003csup\u003e1\u003c/sup\u003e\u003c/h6\u003e\u003cdrupal-media data-entity-type\media\ data-entity-uuid\b45455cb-c811-440c-b503-e051eb2e2499\ data-align\center\\u003e\u0026nbsp;\u003c/drupal-media\u003e\u003cul\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eYou will receive your first infusion, and then a second infusion 2 weeks later\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eAfter that, you will be given an IV infusion every 4 weeks\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eIf you miss an appointment for your infusion, contact your doctor or health care provider as soon as possible to reschedule\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eYour health care provider may also prescribe other treatments for you to take during treatment with ADAKVEO\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eDo not stop receiving ADAKVEO unless your health care provider tells you to\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003cp class\disclaimers-notes\\u003eIV, intravenous.\u003c/p\u003e,format:free_form,processed:\u003ch4 class\heading-01\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003eADAKVEO\u003c/span\u003e\u003cbr\u003e\u0026nbsp;\u003c/h4\u003e\u003ch6 class\heading-03\\u003eADAKVEO is a 30-minute IV infusion given once per month after your second dose\u003csup\u003e1\u003c/sup\u003e\u003c/h6\u003e\u003cdiv class\freeForm__embed\\u003e\u003cpicture\u003e\u003csource media\(max-width:576px)\ srcset\https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/2023-10/adakveo_iv_infusion_timeline_mobile.svg\ width\400\ height\134\\u003e\u003csource media\(max-width:768px)\ srcset\https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/2023-10/adakveo_iv_infusion_timeline_desktop.svg\ width\628\ height\211\\u003e\u003csource media\(max-width:1000px)\ srcset\https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/2023-10/adakveo_iv_infusion_timeline_desktop.svg\ width\688\ height\231\\u003e\u003cimg src\https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/2023-10/adakveo_iv_infusion_timeline_desktop.svg\ loading\lazy\ alt\ADAKVEO dosing schedule\ class\freeForm__img\ width\744\ height\250\\u003e\u003c/picture\u003e\u003c/div\u003e\u003cul\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eYou will receive your first infusion, and then a second infusion 2 weeks later\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eAfter that, you will be given an IV infusion every 4 weeks\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eIf you miss an appointment for your infusion, contact your doctor or health care provider as soon as possible to reschedule\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eYour health care provider may also prescribe other treatments for you to take during treatment with ADAKVEO\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eDo not stop receiving ADAKVEO unless your health care provider tells you to\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003cp class\disclaimers-notes\\u003eIV, intravenous.\u003c/p\u003e},field_icon:,field_icon_bg:{value:gradient_primary_01_primary_03},field_show_icon:{value:false},field_size:{value:full},field_summary:{value:,format:title,processed:,html_element:h1},field_title:{value:,format:title,processed:,html_element:h2},field_under_title:{value:false},field_usim_fuse:},region:content},{id:adc80b7b-63a0-4188-b4af-e1d9cd934e4d,type:single_featured_content_card,weight:4,content:{id:{value:2871},uuid:{value:4903411f-a289-46d4-838c-1d0f1df58d20},type:{target_id:single_featured_content_card,target_type:block_content_type,target_uuid:ffb59f61-5bd7-4407-b78c-e0365a664fe1},top_vertical_spacing:{value:7},bottom_vertical_spacing:{value:3},field_content_alignment:{value:center},field_content_horizont_alignment:{value:left},field_cta_button:,field_info:{value:\u003cp\u003eYou may be eligible for immediate co-pay savings on your next prescription of ADAKVEO.\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cul\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eEligible patients with private insurance may pay as little as $0 for your ADAKVEO treatment each month\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eNovartis will pay the remaining co-pay, up to $15,000 per calendar year\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e,format:global,processed:\u003cp\u003eYou may be eligible for immediate co-pay savings on your next prescription of ADAKVEO.\u003c/p\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cul\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eEligible patients with private insurance may pay as little as $0 for your ADAKVEO treatment each month\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp class\paragraph-01\\u003eNovartis will pay the remaining co-pay, up to $15,000 per calendar year\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e},field_media_caption:{value:,format:title,processed:,html_element:h1},field_media_image:{target_id:506,lightbox:false,target_type:media,target_uuid:bbae24a0-8406-4710-ba4d-e9b086abbde7,url:/media/506/edit,normalized:{id:bbae24a0-8406-4710-ba4d-e9b086abbde7,meta:{field_media_image:{url:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/single_featured_content_card_without_content_width_744/public/2024-09/co-pay-image.png?itokYTWyFZHv,url_webp:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/webp/public/styles/single_featured_content_card_without_content_width_744/public/2024-09/co-pay-image.png.webp?itokt-vwrwXX,type:image/png,width:744,height:490,alt:Novartis Universal Co-Pay Card},field_large_image:{url:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/single_featured_content_card_without_content_width_608/public/2024-09/co-pay-image.png?itokufNkrIRl,url_webp:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/webp/public/styles/single_featured_content_card_without_content_width_608/public/2024-09/co-pay-image.png.webp?itok854xPNYd,type:image/png,width:608,height:401,alt:Novartis Universal Co-Pay Card},field_medium_image:{url:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/single_featured_content_card_without_content_width_552/public/2024-09/co-pay-image.png?itok8seUU3su,url_webp:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/webp/public/styles/single_featured_content_card_without_content_width_552/public/2024-09/co-pay-image.png.webp?itokLSARIY4R,type:image/png,width:552,height:364,alt:Novartis Universal Co-Pay Card},field_extra_small_image:{url:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/common_width_400/public/2024-09/co-pay-image.png?itoksdwCaZEX,url_webp:https://usim.beprod.us.adakveo.com/sites/us_adakveo_com/files/styles/webp/public/styles/common_width_400/public/2024-09/co-pay-image.png.webp?itokvM-MVPGf,type:image/png,width:400,height:264,alt:Novartis Universal Co-Pay Card}}}},field_section_alignment:{value:left},field_size:{value:full},field_small_title:{value:,format:title,processed:,html_element:h6},field_subtitle:{value:\u003cp\u003e\u003cspan class\primary_02-c\ background\primary_02-b\\u003e\u003cstrong\u003eSAVE WITH THE UNIVERSAL CO-PAY PROGRAM\u003c/strong\u003e\u003c/span\u003e\u003c/p\u003e,format:title,processed:\u003cspan class\primary_02-c\ background\primary_02-b\\u003e\u003cstrong\u003eSAVE WITH THE UNIVERSAL CO-PAY PROGRAM\u003c/strong\u003e\u003c/span\u003e,html_element:h5},field_under_title_color:{value:primary_01},field_title:{value:,format:title,processed:,html_element:h2},field_under_title:{value:false},field_usim_fuse:},region:content},{id:d6b9d6e1-1cc7-4095-86f9-40823f571c9d,type:free_form,weight:5,content:{id:{value:2881},uuid:{value:fa6bf6a1-7af6-4ce6-90af-e424c3c85e0f},type:{target_id:free_form,target_type:block_content_type,target_uuid:5c316907-21d0-475c-ae52-1d1709337955},top_vertical_spacing:{value:2},bottom_vertical_spacing:{value:7},field_align:{value:left},field_body:{value:\u003cp class\disclaimers-notes\\u003e*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice.\u003c/p\u003e\u003cp class\disclaimers-notes\\u003eFor full Terms and Conditions, visit \u003ca href\https://copay.novartisoncology.com/\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003eCopay.NovartisOncology.com\u003c/span\u003e\u003c/a\u003e or call 1-877-577-7756.\u003c/p\u003e,format:free_form,processed:\u003cp class\disclaimers-notes\\u003e*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice.\u003c/p\u003e\u003cp class\disclaimers-notes\\u003eFor full Terms and Conditions, visit \u003ca href\https://copay.novartisoncology.com/\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003eCopay.NovartisOncology.com\u003c/span\u003e\u003c/a\u003e or call 1-877-577-7756.\u003c/p\u003e},field_icon:,field_icon_bg:{value:gradient_primary_01_primary_03},field_show_icon:{value:false},field_size:{value:full},field_summary:{value:,format:title,processed:,html_element:h1},field_title:{value:,format:title,processed:,html_element:h2},field_under_title:{value:false},field_usim_fuse:},region:content},{id:16430ff7-ac29-477e-bc5c-4f0f9ec97abe,type:free_form,weight:3,content:{id:{value:2901},uuid:{value:5d6a03cb-825c-475a-9b0d-94e82de5abf7},type:{target_id:free_form,target_type:block_content_type,target_uuid:5c316907-21d0-475c-ae52-1d1709337955},top_vertical_spacing:{value:1},bottom_vertical_spacing:{value:2},field_align:{value:left},field_body:{value:\u003cp class\paragraph-01\\u003e\u003cspan class\neutral_70-c\\u003e\u003cstrong\u003eNovartis Patient Support is a program to help you start, stay, and save on your ADAKVEO treatment. To learn more, call 1-800-282-7630.\u003c/strong\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\u003ch5 class\heading-02\\u003e\u003cspan class\primary_03-c\ background\primary_03-b\\u003eUniversal Co-pay Program\u003c/span\u003e\u003c/h5\u003e,format:free_form,processed:\u003cp class\paragraph-01\\u003e\u003cspan class\neutral_70-c\\u003e\u003cstrong\u003eNovartis Patient Support is a program to help you start, stay, and save on your ADAKVEO treatment. To learn more, call 1-800-282-7630.\u003c/strong\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\u003ch5 class\heading-02\\u003e\u003cspan class\primary_03-c\ background\primary_03-b\\u003eUniversal Co-pay Program\u003c/span\u003e\u003c/h5\u003e},field_icon:,field_icon_bg:{value:gradient_primary_01_primary_03},field_show_icon:{value:false},field_size:{value:full},field_summary:{value:,format:title,processed:,html_element:h1},field_title:{value:,format:title,processed:,html_element:h2},field_under_title:{value:false},field_usim_fuse:},region:content},{id:2410f533-571a-4dd1-9e02-57dc14df1b82,type:hero_text,weight:2,content:{id:{value:2911},uuid:{value:14d5fd14-d100-43e6-9c61-ba9ece1f3c82},top_vertical_spacing:{value:4},bottom_vertical_spacing:{value:0},field_background_color:{value:primary_01},field_body:,field_cta_buttons:,field_hero_text_align:{value:center},field_hero_text_size:{value:eight-columns},field_title:{value:\u003cp\u003e\u003cspan class\neutral_0-c\\u003e\u003cstrong\u003eNovartis Patient Support™\u003c/strong\u003e\u003c/span\u003e\u003c/p\u003e,format:title,processed:\u003cspan class\neutral_0-c\\u003e\u003cstrong\u003eNovartis Patient Support™\u003c/strong\u003e\u003c/span\u003e,html_element:h1},field_under_title:{value:false},field_usim_fuse:},region:content}},{id:layout_pre_footer,title:refs,components:{id:0609796f-e002-4fe5-8900-83cfad9347c4,type:footnote,weight:0,content:{id:{value:2896},uuid:{value:2a844e92-591c-424f-b378-9547372c8ad9},top_vertical_spacing:{value:7},bottom_vertical_spacing:{value:7},field_cta_buttons:,field_info:{value:\u003cp\u003e\u003cstrong\u003eReference: 1.\u003c/strong\u003e\u0026nbsp;Adakveo. Prescribing information. Novartis Pharmaceuticals Corp.\u003c/p\u003e,format:global_w_o_p,processed:\u003cstrong\u003eReference: 1.\u003c/strong\u003e\u0026nbsp;Adakveo. Prescribing information. Novartis Pharmaceuticals Corp.},field_size:{value:full},field_usim_fuse:},region:content}},error:null,uspFuseCode:8/24 FA-11246840,irmaConfig:null,multiIndicationTaxonomies:null,ISIConfig:{version:2,isEnabled:true,isExpanded:false,ISITitle:\u003cstrong\u003eImportant Safety Information\u003c/strong\u003e,ISITitleTag:h2,shortISIBody:\u003cp\u003e\u003cstrong\u003eWhat is the most important information I should know about ADAKVEO?\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eADAKVEO may cause serious side effects, including infusion-related reactions.\u0026nbsp;\u003c/strong\u003e\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eInfusion-related reactions.\u003c/strong\u003e\u0026nbsp;Infusion-related reactions may happen during or within 24\u0026nbsp;hours of receiving an infusion of ADAKVEO. Infusion-related reactions may cause pain in different areas of your body...\u003c/p\u003e,fullISIBody:\u003cp\u003e\u003cstrong\u003eWhat is the most important information I should know about ADAKVEO?\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eADAKVEO may cause serious side effects, including infusion-related reactions.\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eInfusion-related reactions.\u003c/strong\u003e\u0026nbsp;Infusion-related reactions may happen during or within 24\u0026nbsp;hours of receiving an infusion of ADAKVEO. Infusion-related reactions may cause pain in different areas of your body. Your health care provider may slow down, temporarily stop, or completely stop your infusion with ADAKVEO if you have an infusion-related reaction. You may continue to receive ADAKVEO at a slower infusion rate, and your health care provider may give you certain medicines before your infusion to lower your risk of getting an infusion-related reaction. Your health care provider should monitor you for signs and symptoms of infusion-related reactions and treat your symptoms as needed. Tell your health care provider right away if you get any of the following signs and symptoms of an infusion-related reaction:\u003c/p\u003e\u003cul\u003e\u003cli\u003epain in various locations\u003c/li\u003e\u003cli\u003eheadache\u003c/li\u003e\u003cli\u003efever\u003c/li\u003e\u003cli\u003echills or shivering\u003c/li\u003e\u003cli\u003enausea\u003c/li\u003e\u003cli\u003evomiting\u003c/li\u003e\u003cli\u003ediarrhea\u003c/li\u003e\u003cli\u003etiredness\u003c/li\u003e\u003cli\u003edizziness\u003c/li\u003e\u003cli\u003esweating\u003c/li\u003e\u003cli\u003ehives\u003c/li\u003e\u003cli\u003eitching\u003c/li\u003e\u003cli\u003eshortness of breath or wheezing\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eADAKVEO may interfere with a blood test.\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eTell your health care provider that you are receiving ADAKVEO before having any blood tests. ADAKVEO may interfere with a laboratory test to measure your platelet counts.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eBefore receiving ADAKVEO, tell your health care provider about all of your medical conditions, including if you\u003c/strong\u003e\u003c/p\u003e\u003cul\u003e\u003cli\u003eare pregnant or plan to become pregnant. ADAKVEO may harm your unborn baby. Talk to your health care provider about the possible risk to your unborn baby if you take ADAKVEO during pregnancy\u003c/li\u003e\u003cli\u003eare breastfeeding or plan to breastfeed. It is not known if ADAKVEO passes into your breast milk. You and your health care provider should decide the best way to feed your baby during treatment with ADAKVEO\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u003cstrong\u003eTell your health care provider about all of the medicines you take\u003c/strong\u003e, including prescription and over-the-counter medicines, vitamins, and herbal supplements.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eThe most common side effects of ADAKVEO include:\u003c/strong\u003e\u003c/p\u003e\u003cul\u003e\u003cli\u003eheadache\u003c/li\u003e\u003cli\u003ejoint pain\u003c/li\u003e\u003cli\u003enausea\u003c/li\u003e\u003cli\u003eback pain\u003c/li\u003e\u003cli\u003efatigue\u003c/li\u003e\u003cli\u003estomach pain\u003c/li\u003e\u003cli\u003efever\u003c/li\u003e\u003cli\u003ediarrhea\u003c/li\u003e\u003cli\u003evomiting\u003c/li\u003e\u003cli\u003ethroat pain\u003c/li\u003e\u003c/ul\u003e\u003cp\u003eThese are not all of the possible side effects of ADAKVEO. For more information, ask your health care provider or pharmacist.\u003c/p\u003e\u003cp\u003eCall your doctor for medical advice about side effects.\u003c/p\u003e\u003cp\u003eYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit\u0026nbsp;\u003ca href\https://fda.gov/medwatch\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003ewww.fda.gov/medwatch\u003c/span\u003e\u003c/a\u003e, or call\u0026nbsp;\u003ca href\tel: 1-800-332-1088\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003e1-800-FDA-1088\u003c/span\u003e\u003c/a\u003e.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003ePlease see accompanying full\u0026nbsp;\u003c/strong\u003e\u003ca href\https://www.novartis.com/us-en/sites/novartis_us/files/adakveo.pdf\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003e\u003cstrong\u003ePrescribing Information\u003c/strong\u003e\u003c/span\u003e\u003c/a\u003e\u003cstrong\u003e, including\u0026nbsp;\u003c/strong\u003e\u003ca href\https://www.novartis.com/us-en/sites/novartis_us/files/adakveo.pdf#page11\ target\_blank\ rel\noopener\\u003e\u003cspan class\primary_01-c\ background\primary_01-b\\u003e\u003cstrong\u003ePatient Information\u003c/strong\u003e\u003c/span\u003e\u003c/a\u003e\u003cstrong\u003e.\u003c/strong\u003e\u003c/p\u003e,genericPromptFull:\u003cstrong\u003eClick or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE\u003c/strong\u003e,genericPromptMobile:\u003cstrong\u003eTap to see IMPORTANT SAFETY INFORMATION AND APPROVED USE\u003c/strong\u003e,isEnableIndication:true,indicationTitle:\u003cstrong\u003eApproved Use\u003c/strong\u003e,indicationTitleTag:h2,shortIndicationBody:\u003cp\u003e\u003cstrong\u003eWhat is ADAKVEO\u003csup\u003e®\u003c/sup\u003e\u0026nbsp;(crizanlizumab-tmca)?\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eADAKVEO is a prescription medicine used in people 16 years of age and older who have sickle cell disease to help reduce how often painful crises happen.\u003c/p\u003e\u003cp\u003eIt is not known if ADAKVEO is safe and effective in children under 16 years of age...\u003c/p\u003e,fullIndicationBody:\u003cp\u003e\u003cstrong\u003eWhat is ADAKVEO\u003csup\u003e®\u003c/sup\u003e\u0026nbsp;(crizanlizumab-tmca)?\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eADAKVEO is a prescription medicine used in people 16 years of age and older who have sickle cell disease to help reduce how often painful crises happen.\u003c/p\u003e\u003cp\u003eIt is not known if ADAKVEO is safe and effective in children under 16 years of age.\u003c/p\u003e,ISIFontSize:paragraph-03,fuseCodeDisplay:null,fuseCodeText:null,fuseCodeAlignment:null},kalturaVersion:v7,schemaScripts:},__N_SSP:true},page:/,query:{},buildId:NalTJwMYG2qxqZ3I_yxAX,isFallback:false,isExperimentalCompile:false,gssp:true,appGip:true,scriptLoader:{src:/scripts/web-vitals.min.js,strategy:afterInteractive}}/script>/body>/html>
Subdomains
Date
Domain
IP
usim.beprod.us.adakveo.com
2024-05-06
172.64.154.154
www.us.adakveo.com
2026-02-24
172.64.154.154
www.adakveo.com
2024-07-19
45.60.11.232
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]